Table 1 Patient baseline characteristics at the time of initial diagnosis and treatment types (n = 48)
Characteristics | Median (range)/no. of patients (%) | ||
|---|---|---|---|
Total | Group A | Group B | |
No. of patients | 48 | 36 | 12 |
Age (yr), median (range) | 53 (36–77) | 54 (37–68) | 47 (36–77) |
ECOG performance status score | |||
0 | 33 (68.8) | 26 (72.2) | 7 (58.3) |
1 | 11 (22.9) | 7 (19.4) | 4 (33.3) |
2 | 4 (8.3) | 3 (8.3) | 1 (8.3) |
Histological subtype | |||
Squamous cell carcinoma | 39 (81.3) | 32 (88.9) | 7 (58.3) |
Small-cell neuroendocrine carcinoma | 4 (8.3) | 1 (2.8) | 3 (25.0) |
Adenocarcinoma | 3 (6.3) | 2 (5.6) | 1 (8.3) |
Adeno-squamous cell carcinoma | 1 (2.1) | 1 (8.3) | |
Sarcoma | 1 (2.1) | 1 (2.8) | |
Primary tumor size (cm) | |||
≥ 4-cm | 39 (81.3) | 30 (83.3) | 9 (75.0) |
< 4-cm | 9 (18.8) | 6 (16.7) | 3 (25.0) |
Pre-treatment Hb (g/dL) | |||
> 10 | 37 (77.1) | 29 (80.6) | 8 (66.7) |
≤ 10 | 11 (22.9) | 7 (19.4) | 4 (33.3) |
Pre-treatment WBC(10^9 /L) | |||
> 10 | 8 (16.7) | 6 (16.7) | 2 (16.7) |
≤ 10 | 40 (83.3) | 30 (83.3) | 10 (83.3) |
Diagnostic methods of metastatic lesions | |||
CT/MRI/ECT | 23 (47.9) | 18 (50.0) | 5 (41.7) |
PET-CT | 19 (39.6) | 14 (38.9) | 5 (41.7) |
Biopsy | 6 (12.5) | 4 (11.1) | 2 (16.7) |
Initial treatment | |||
Chemotherapy cycle | 4 (2–8) | 4 (2–7) | 4 (3–8) |
Pelvic primary tumor radiotherapy | 42 (87.5%) | 36 (100%) | 5 (41.7%) |
Sites of organ metastasis radiotherapy | 19 (39.6%) | 17 (47.2%) | 2 (16.7%) |
Primary tumor radiotherapy dose (Gy) | |||
External dose | 45.9 (45–50.4) | 37.8 (10.8–46.8) | |
ICBT dose | 28 (23–34.5) | ||
Point A dose (EQD2) | 80.4 (72.3–87) | ||